vimarsana.com

Latest Breaking News On - Cardiology late breaking clinical - Page 1 : vimarsana.com

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session & Expo

Statins may prevent cardiac dysfunction in patients taking anthracyclines

NEW ORLEANS — In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma.“Anthracyclines are a standard chemotherapy drug used in the treatment of breast cancer and lymphoma. Anthracyclines are prescribed to more than 1

Transcatheter edge-to-edge repair shows benefit for severe tricuspid regurgitation

NEW ORLEANS — Treatment of severe tricuspid regurgitation with transcatheter repair was safe, reduced severity of tricuspid regurgitation and led to improvements in quality of life at 1 year, according to results of the TRILUMINATE Pivotal trial. “[The] TRILUMINATE Pivotal [trial] is a pioneering study as the first randomized clinical trial in this unique population of patients with

Bempedoic acid an effective alternative for statin-intolerant patients: CLEAR Outcomes

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.